Update:
Amfora continued to make both R&D and commercial progress during Q2 of 2021. Although we had a setback in advancing our first generation of gene edited soybean lines, we have aggressively advanced our second-generation program, including a publicly announced program with Plastomics.

Amfora continues to advance its commercial development progress by accessing high protein germplasm; initiating a soybean breeding effort; initiating wide area germplasm testing across the Midwest; producing tons of ultra-high protein soybean meal; initiating a food science program to demonstrate the utility of ultra-high protein soy in formulating plant-based meat; and initiating aquaculture feeding studies.